Shares of Innovent Biologics Inc. soared over 5% in morning trading on August 21, after the Chinese biopharmaceutical company announced a major regulatory approval for its novel cancer drug Dupert.
According to the company's announcement, China's National Medical Products Administration (NMPA) has granted approval for Dupert (surtanuvifefuli) as the country's first KRAS G12C inhibitor for the treatment of advanced solid tumors harboring the KRAS G12C mutation.
The KRAS G12C mutation is a key driver of cancer growth and is present in approximately 13% of non-small cell lung cancers, 3-5% of colorectal cancers, and a range of other solid tumor types. Dupert is designed to inhibit this specific mutation, representing a breakthrough in targeted cancer therapy.
Comments